NanoViricides, Inc. (NYSE American: NNVC) announced on [date not provided] a securities purchase agreement with a single institutional investor for a registered direct offering expected to generate approximately $2 million in gross proceeds. The offering involves the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants carry an exercise price of $1.75 per share and a three-year term, with closing expected on or about May 18, 2026, subject to customary conditions. The full press release is available at https://ibn.fm/Z8Etj.
This capital raise is significant for NanoViricides as it provides funding to advance its clinical-stage pipeline. The company is a clinical-stage, broad-spectrum antiviral developer based on host-mimetic nanomedicine technology. Its lead drug candidate, NV-387, has been granted Orphan Drug Designation (ODD) by the U.S. FDA Office of Orphan Products Development (OOPD) for the treatment of a yet-unspecified indication. ODD provides benefits such as seven years of market exclusivity upon approval, tax credits for clinical trial costs, and fee exemptions. NV-387 is designed as a broad-spectrum antiviral and has shown efficacy in lethal animal infection models for Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles. The company believes NV-387 could become a first-line treatment for patients presenting with respiratory viral illnesses.
The offering underscores investor confidence in NanoViricides' approach and the potential of NV-387. The funds will likely be used to support ongoing clinical trials and manufacturing scale-up. The company's technology platform is designed to create antivirals that viruses and their variants cannot escape, positioning it as a leader in the field. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.
The offering is a registered direct offering, meaning the securities are sold directly to the investor without an underwriter, which can reduce costs and time. The pre-funded warrants allow the investor to purchase shares at a nominal cost, effectively acting as a substitute for shares if the investor prefers. This structure is common in offerings where the share price is low relative to the offering amount. The warrants have an exercise price of $1.75, which may provide additional capital if exercised.
Overall, this capital infusion is a positive step for NanoViricides as it seeks to advance NV-387 through clinical development and potentially bring a broad-spectrum antiviral to market. The company's focus on host-mimetic nanomedicine technology differentiates it from traditional antiviral approaches, which often face resistance from viral mutations. With ODD and promising preclinical data, NV-387 has the potential to address significant unmet medical needs in viral infections.
